bbba6e8b-9e37-45e0-b663-f81631e76828
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SAMN03290896 | — | — | 0.903 |
| 2 | f0a22b8b-4cf5-4edc-9502-1e01839fa7c7 | — | — | 0.883 |
| 3 | a277c487-2d13-460f-a0d8-26acac1657d0 | — | — | 0.879 |
| 4 | MDT-AP-3273 | Med | Medulloblastoma | 0.878 |
| 5 | TCGA-D6-6827-01A-11R-1915-07 | — | — | 0.869 |
| 6 | ERR2208946 | — | — | 0.868 |
| 7 | b68594bb-fca3-4f05-a9fa-1e6e88eb4fc5 | — | — | 0.867 |
| 8 | SRR975552 | — | — | 0.859 |
| 9 | SAMN03290918 | — | — | 0.854 |
| 10 | SRR8613756 | — | E | 0.854 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 5 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.500 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.200 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.200 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |